Skip to main content
American Journal of Public Health logoLink to American Journal of Public Health
. 1990 May;80(5):590–593. doi: 10.2105/ajph.80.5.590

Persistence of anti-HBs among health care personnel immunized with hepatitis B vaccine.

M T Pasko 1, T R Beam Jr 1
PMCID: PMC1404632  PMID: 2139306

Abstract

Health care personnel who received the hepatitis B vaccine (Heptavax-BR, MSD) were followed for persistence of hepatitis B surface antibody (anti-HBs). Response occurred in 135/146 (92.5 percent) vaccinees. Loss of anti-HBs (less than 72 RIA units; 10 S/N) occurred in 35.9 percent during the 36-month surveillance. Stepwise discriminant analysis found age and magnitude of initial antibody level, but not weight-height index, to be predictive of antibody loss over the 36 months. Twenty-four of 27 employees (88.9 percent) who lost anti-HBs responded to a fourth vaccine dose. In contrast, three of eight initial non-responders (37.5 percent) developed antibody after a fourth vaccine dose.

Full text

PDF
590

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnas G. P., Hanacik L. J. Hepatitis B vaccine: persistence of antibody following immunization. Infect Control Hosp Epidemiol. 1988 Apr;9(4):147–150. doi: 10.1086/645818. [DOI] [PubMed] [Google Scholar]
  2. Berry A. J., Isaacson I. J., Hunt D., Kane M. A. The prevalence of hepatitis B viral markers in anesthesia personnel. Anesthesiology. 1984 Jan;60(1):6–9. doi: 10.1097/00000542-198401000-00003. [DOI] [PubMed] [Google Scholar]
  3. Denes A. E., Smith J. L., Maynard J. E., Doto I. L., Berquist K. R., Finkel A. J. Hepatitis B infection in physicians. Results of a nationwide seroepidemiologic survey. JAMA. 1978 Jan 16;239(3):210–212. [PubMed] [Google Scholar]
  4. Dienstag J. L., Ryan D. M. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol. 1982 Jan;115(1):26–39. doi: 10.1093/oxfordjournals.aje.a113277. [DOI] [PubMed] [Google Scholar]
  5. Dienstag J. L., Werner B. G., Polk B. F., Snydman D. R., Craven D. E., Platt R., Crumpacker C. S., Ouellet-Hellstrom R., Grady G. F. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med. 1984 Jul;101(1):34–40. doi: 10.7326/0003-4819-101-1-34. [DOI] [PubMed] [Google Scholar]
  6. Fagan E. A., Tolley P., Smith H. M., Peters M. P., Coleman J., Elliott P., Williams R., Eddleston A. L. Hepatitis B vaccine: immunogenicity and follow-up including two year booster doses in high-risk health care personnel in a London teaching hospital. J Med Virol. 1987 Jan;21(1):49–56. doi: 10.1002/jmv.1890210107. [DOI] [PubMed] [Google Scholar]
  7. Gardner M. J., Altman D. G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed) 1986 Mar 15;292(6522):746–750. doi: 10.1136/bmj.292.6522.746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hadler S. C., Francis D. P., Maynard J. E., Thompson S. E., Judson F. N., Echenberg D. F., Ostrow D. G., O'Malley P. M., Penley K. A., Altman N. L. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986 Jul 24;315(4):209–214. doi: 10.1056/NEJM198607243150401. [DOI] [PubMed] [Google Scholar]
  9. Horowitz M. M., Ershler W. B., McKinney W. P., Battiola R. J. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med. 1988 Feb;108(2):185–189. doi: 10.7326/0003-4819-108-2-185. [DOI] [PubMed] [Google Scholar]
  10. Jilg W., Schmidt M., Deinhardt F., Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet. 1984 Aug 25;2(8400):458–458. doi: 10.1016/s0140-6736(84)92926-x. [DOI] [PubMed] [Google Scholar]
  11. Klotz S. A., Normand R., Silberman R. Hepatitis B vaccine in healthy hospital employees. Infect Control. 1986 Jul;7(7):365–369. doi: 10.1017/s0195941700064481. [DOI] [PubMed] [Google Scholar]
  12. Wainwright R. B., McMahon B. J., Bulkow L. R., Hall D. B., Fitzgerald M. A., Harpster A. P., Hadler S. C., Lanier A. P., Heyward W. L. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA. 1989 Apr 28;261(16):2362–2366. [PubMed] [Google Scholar]
  13. Weber D. J., Rutala W. A., Samsa G. P., Santimaw J. E., Lemon S. M. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 1985 Dec 13;254(22):3187–3189. [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES